Research Projects & Grants

• Longitudinal Variations in Serum Bone Markers, Role: PI, (01/1993 - 01/1994) Status: Completed
• The Long-Term Effects of Fluoride Ingestion in Persons Afflicted with Osteoporosis, Role: PI, (06/1992 - 06/1993) Status: Completed

Federal

• Acquisition of a Zeiss LSM 900 confocal microscope with Airyscan 2 for an Imaging and Microscopy Core, Role: Minor User, National Institutes of Health/DHHS, (05/2023 - 05/2024) Status: Closed
• Targeting Intestinal Stem Cells to Augment the Repair of Epithelial Barrier, Role: Other Significant Contributor, National Institute of Allergy and Infectious Diseases/NIH/DHHS, (02/2019 - 06/2019) Status: Closed
• LLU-NIH Initiative for Maximizing Student Development, Role: Other Significant Contributor, National Institute of General Medical Sciences/NIH/DHHS, (01/2018 - 12/2023) Status: Closed
• Maternal renal VDR regulation during pregnancy, Role: Other Significant Contributor, National Institute of Child Health and Human Development/NIH/DHHS, (02/2016 - 01/2019) Status: Closed
• High Throughput DNA Sequencer, Role: Minor User, National Institutes of Health/DHHS, (04/2015 - 04/2016) Status: Closed
• 10082008: Cell and Molecular Study of Skeletal Augmentation and Repair, Role: PD/PI, Department of the Army, (04/2012 - 10/2018) Status: Closed
• iPSC-derived MSCs that are Genetically Engineered for Systemic Bone Augmentation, Role: Co-Investigator, Department of Defense, (07/2011 - 07/2013) Status: Closed
• Targeted Stem Cell-gene Therapy for Inflammatory Brain Disease, Role: Principal Investigator, U.S. Army Medical Research & Material Command, (12/2010 - 12/2013) Status: Closed
• Cell and Molecular Study of Skeletal Augmentation and Repair, Role: Principal Investigator, United States Army, (09/2008 - 02/2012) Status: Closed
• Genetic and dynamic analysis of murine bone size, Role: Key, National Institutes of Health/DHHS, (07/2002 - 06/2003) Status: Closed
• Research training in biomedical studies of bone, National Institutes of Health/DHHS, (05/2002 - 04/2003) Status: Closed
• Research training in biomedical studies of bone, National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS, (05/2001 - 04/2002) Status: Closed
• Studies on the mechanism of age-related decline in serum insulin-like growth factor-I, Role: Investigator, LLVARE, Status: Completed

For Profit Organization

• Continuing outcomes relevant to evista (CORE): A study of raloxifene HCl and placebo in the prevention of invasive breast cancer in postmenopausal women with osteoporosis, Role: PI, Eli Lilly & Co., (05/2003 - 05/2004) Status: Completed
• A multicenter, double-blind, randomized, active-controlled, parallel group study of daily vs weekly dosing regimens of risedronate in the treatment of osteoporosis in post menopausal women, Role: PI, Procter & Gamble Company, (06/2001 - 06/2002) Status: Completed
• Multicenter, double-blind, placebo-controlled, randomized study on the efficacy and safety of ibandronate during 3 years' treatment in patients with menopausal osteoporosis and verterbral fractures using a continuous oral (2.5. mg daily) and an intermittent oral (20 mg every 2nd day for 24 days every 3 months) dosing regiment (MF-4411), Role: PI, Boehringer Mannheim GmbH, (09/2000 - 09/2001) Status: Completed
• Double-blind, placebo-controlled, randomized, multicenter study on the efficacy and safety of ibandronate (BM 21.0955) during an extended 2-year partial crossover study of patients enrolled in MF 4380 (3-year postmenopausal osteoporosis treatment study) using an i.v. injection regimen of 0.5 mg and 1 mg every 3 months (MF 4492), Role: PI, Roche Global Development, (12/1999 - 12/2000) Status: Completed
• A long term open label extension trial of a single daily dose of idoxifene in postmenopausal women, Role: PI, Smithkline Beecham, (11/1999 - 11/2000) Status: Completed
• A multi-center, double-blind, randomized study of continuous transdermal estrodiol-levonorgestrel combinations, compared to continuous transdermal estradiol, to examine the safety and effect on the endometrium, symptoms, and bleeding patterns in postmenopausal women (Protocol 96043), Role: PI, Berlex Laboratories Inc., (11/1999 - 11/2000) Status: Completed
• A multicenter, double-blind, randomized comparison of continuous oral estradiol-drospirenone combinations and continouous oral estradiol, examining the effect on the endometrium and bleeding patterns in postmenopausal women, Role: PI, Berlex Pharmaceuticals, (10/1999 - 10/2000) Status: Completed
• An open label, long term tolerability study of pioglitazaone (AD-4833) in type II diabetes mellitus patients (non-insulin dependent diabetes mellitus, NIDDM), Role: Investigator, Takeda America Research and Development Center Inc, (09/1999 - 09/2000) Status: Completed
• A double-blind, randomized, placebo-controlled, multicenter study to evaluate upper GI tolerability upon rechallenge in postmenopausal women with osteoporosis who previously discontinued alendronate due to upper gastrointestinal symptoms (Protocol No. 149-00), Role: PI, Merck, Sharp, and Dohme (MSD) Research Foundation, (08/1999 - 07/2000) Status: Completed
• A randomized, double blind, placebo controlled trial of the effect of Idoxifene in the prevention of bone loss in early postmenopausal women (protocol No. 015) SB-223030., Role: PI, Smithkline Beecham, (07/1999 - 07/2000) Status: Completed
• A randomized, double blind, placebo controlled trial of the effect of Idoxifene in the prevention of osteoporosis in postmenopausal women with low bone mineral density (protocol No. 016) SB-223030, Role: PI, Smithkline Beecham, (07/1999 - 07/2000) Status: Completed
• Double-Blind, Placebo-Controlled, Randomized, Multicenter Study on the Efficacy and Safety of Ibandronate (BM 21,0955) During Three Years Treatment in Patients with Postmenopausal Osteoporosis Using an Intermittent (Every 3 Months) I.V. Injection Regimen, Role: PI, Boehringer Mannheim GmbH, (06/1999 - 05/2000) Status: Completed
• A clinical evaluation of the effect of Estradiol TD and Ethicombi TD, used sequentially, on Estradiol-induced endometrial hyperplasia (Protocol No. EPCOUS01), Role: PI, Ethical Pharmaceutical, (03/1999 - 03/2000) Status: Completed
• Clinical protocol for a multicenter, double-blind, parallel group study comparing the incidence of clinically significant upper gastrointestinal adverse events associated with SC-58635 400 mg BID to that ibuprofin 800 mg in patients with osteoarthritis or rheumatoid arthritis (Protocol No. N49-98-02-035), Role: Investigator, Searle, (03/1999 - 03/2000) Status: Completed
• A study to establish the normal reference range for biochemical markers of skeletal metabolism (11/6/98), Role: PI, Bio-Rad, (12/1998 - 11/1999) Status: Completed
• A multi-center, double blind, controlled, randomized study to determine efficacy in the relief of hot flashes in women receiving transdermal estradiol compared to oral conjugated estrogens (Protocol No. 97095, 7/18/97), Role: PI, Berlex Pharmaceuticals, (10/1998 - 10/1999) Status: Completed
• Comparison of Raloxifen HCl and placebo in the treatment of postmenopausal women with osteoporosis, Role: PI, Eli Lilly & Co., (09/1998 - 09/1999) Status: Completed
• A six-month, double blind, randomized, placebo-controlled, multicenter, parallel-group trial to evaluate the safety of modified dosing instructions for 5 mg oral risedronate in postmenopausal osteopenic and osteoporotic women (Protocol dated 4/3/98), Role: PI, Procter & Gamble Company, (06/1998 - 06/1999) Status: Completed
• A Randomized Double-Blind Placebo-Controlled Multi-center Parallel Group Study to Determine the Efficacy and Safety of Risodronate (NE-58095) in the Treatment of Postmenopausal Women with Established Osteoporosis Related Vertebral Deformities, Role: PI, Procter & Gamble Company, (01/1998 - 01/1999) Status: Completed
• Use of biometrics incorporated in the quantitative measurement of pyridinoline in human sweat, Role: PI, Pacific Biometrics Incorporated, (08/1997 - 08/1998) Status: Completed
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of Risedronate in the Treatment of Osteoporosis in Elderly Women, Role: PI, Procter & Gamble Company, (06/1997 - 06/1998) Status: Completed
• A multi-center, randomized, double-blind, placebo-controlled dose-finding study to evaluate the efficacy and safety of Tibolone (ORG OD 14) in prevention of osteoporosis in postmenopausal women, Role: PI, Organon USA Inc., (04/1997 - 04/1998) Status: Completed
• A Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75 and 100 ug) in the Treatment of Postmenopausal Osteoporosis (Protocol ALX1-11-821), Role: PI, Allelix Biopharmaecuticals, (04/1997 - 04/1998) Status: Completed
• A Triple-Blind, Randomized, Active Controlled, Parallel Group Multicenter Study to Evaluate and Compare the Efficacy and Tolerability of Alendronate Sodium with Calcium Supplementation in the Treatment of Osteoporosis in Postmenopausal Women (Protocol #088-00), Role: PI, Merck, Sharp, and Dohme (MSD) Research Foundation, (03/1997 - 03/1998) Status: Completed
• A randomized, double blind, placebo-controlled, dose ranging trial of the effect of Idoxifene on biochemical markers of bone turnover in postmenopausal women (Protocol 0141 SB-223030/Idoxifene), Role: PI, Smithkline Beecham, (07/1996 - 07/1997) Status: Completed
• A Study to Determine the Efficacy of Salmon Calcitonin Nasal Spray in the Treatment of Steroid-Induced Osteoporosis, Role: PI, Sandoz Pharmaceutical Co., (04/1996 - 04/1997) Status: Completed
• A randomized, double-blind, placebo-controlled, multicenter, parallel group study to compare the efficacy and safety of Risedronate (NE-58095) plus estrogen versus estrogen only in the prevention of bone loss in postmenopausal women (no. RPE-002494), Role: PI, Procter & Gamble Company, (07/1995 - 07/1996) Status: Completed
• Evaluation of a New High Resolution Multi-detector DXA Device: The Hologic QDR-4500, Role: PI, Hologic Inc., (07/1995 - 07/1996) Status: Completed
• MFP-SR Pharmacokinetics, Role: PI, ASTA Medica, (04/1995 - 04/1996) Status: Completed

Internal

• Combination of Anti-PD1 Therapy and Tumor Infiltrating Lymphocytes for the Treatment of Acute Myeloid Leukemia., Role: Other Significant Contributor, LLU - GRASP, (01/2020 - 06/2025) Status: Awarded
• Harnessing T cells to Regenerate Articular Cartilage, Role: PD/PI, LLU School of Medicine, (01/2019 - 12/2022) Status: Closed
• Combination therapy of low dose 5-Azacytidine and cell therapy, Role: Other Significant Contributor, LLU Dept. of Medicine, (02/2018 - 02/2023) Status: Closed
• Direct Delivery of a Therapeutic dose of the Active Vitamin D Metabolite to the Immune System for Specific Control of Experimental Autoimmune Encephalomyelitis, Role: Mentor, LLU School of Medicine, (02/2015 - 02/2020) Status: Closed
• A pilot study of sustained sodium monofluorophosphate (MFPSR) given cyclically for established osteoporosis, Role: PI, LLU Dept. of Medicine, (06/1999 - 06/2000) Status: Completed
• Use of combined PTH 1-34 and slow-release monofluorophosphate in the treatment of established postmenopausal osteoporosis compared to therapy with PTH 1-34 or slow-release monofluorophosphate alone, Role: PI, LLU Dept. of Medicine, (12/1997 - 12/1998) Status: Completed
• Determination of half-life of fluoride and serum bone formation markers after discontinuation of fluoride therapy for osteoporosis-a pilot study, Role: PI, LLU, (11/1997 - 11/1998) Status: Completed
• Assessment and treatment following completion of parathyroid hormone therapy for post-menopausal osteoporosis, Role: PI, LLU Dept. of Medicine, (07/1997 - 07/1998) Status: Completed
• A pilot study to assess the effects of hemopoietic stem cell transplantation on skeletal metabolism, Role: Investigator, LLU Dept. of Medicine, Status: Completed

Non-Profit Organization

• Gene transduced mesenchymal progenitor cell for Vitamin D delivery in acute myeloid leukemia, Role: Mentor, American Society of Clinical Oncology, (07/2017 - 06/2018) Status: Closed
• A multicenter, double-blind, randomized study of continous transdermal estradiol-levonorgestrel combinations, examining the effect on the endometrium, and bleeding patterns in previously randomized postmenopausal women who have completed 13 cycles (1 year) of estradiol-levonorgestrel hormone replacement therapy (Protocol No. 98189, 05/24/99), Role: PI, Berlex Foundation, (11/2000 - 11/2001) Status: Completed
• A Multicentered, Double-blind, Randomized Study to Investigate the Efficacy of Miacalcin Nasal Spray (Salmon Calcitonin) in the Prevention of Osteoporotic Vertebral Fractures, Role: PI, Sandoz Research Institute, (03/1999 - 03/2000) Status: Completed
• A triple-blind, randomized, placebo-controlled multicenter study to compare efficacy of oral alendronate sodium to intranasal calcitonin-salmon for treatment of postmenopausal osteoporosis, Role: PI, Merck Company Foundation, (03/1999 - 03/2000) Status: Completed

State

• Cell therapy for acute myeloid leukemia using hematopoietic stem cell as a vehicle, Role: PD/PI, California Institute for Regenerative Medicine, (04/2018 - 03/2019) Status: Closed